Full Press Release Details
REGENERON INITIATES PHASE II CLINICAL TRIAL OF IL1 TRAP IN PATIENTS WITH RHEUMATOID ARTHRITIS Lead Compound in Regeneron's Custom-designed Trap Program Advances in Clinic.
REGN
REGENERON INITIATES PHASE II CLINICAL TRIAL OF IL1 TRAP IN PATIENTS WITH RHEUMATOID ARTHRITIS Lead Compound in Regeneron's Custom-designed Trap Program Advances in Clinic
Key Takeaway: REGENERON INITIATES PHASE II CLINICAL TRIAL OF IL1 TRAP IN PATIENTS WITH RHEUMATOID ARTHRITIS Lead Compound in Regeneron's Custom-designed Trap Program Advances in Clinic
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
2.7%
average across 15 past catalysts
Lead asset
REGN7508
Phase 3 · Venous Thromboembolism